Skip to main content
. Author manuscript; available in PMC: 2020 Dec 4.
Published in final edited form as: Sci Transl Med. 2019 Sep 11;11(509):eaaw8412. doi: 10.1126/scitranslmed.aaw8412

Figure 1. Cell competition assays to test the essentiality of putative cancer dependencies.

Figure 1.

(A) Schematic of the CRISPR-based cell competition assays used in this paper (18).

(B) Cell competition assays comparing guides targeting AAVS1 and ROSA26 (non-essential, negative control genes), RPA3 and PCNA (pan-essential positive control proteins), and Aurora A, Aurora B, and ERCC3 (inhibitor-validated cancer dependencies). Full results from these competition experiments are included in data file S2.

(C) Cell competition assays for the cell type-specific cancer dependencies BRAF and ESR1.

(D) Western blot analysis of A375 populations transduced with the indicated guide RNAs.

(E) Cell competition assays with guide RNAs targeting HDAC6, MAPK14, PAK4, PBK, or PIM1 in four different cancer cell lines.